361 related articles for article (PubMed ID: 19943753)
1. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation.
Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
J Drug Target; 2010 May; 18(4):292-302. PubMed ID: 19943753
[TBL] [Abstract][Full Text] [Related]
2. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
Razeghinejad MR; Sawchyn AK; Katz LJ
Expert Opin Pharmacother; 2010 Apr; 11(6):959-68. PubMed ID: 20307220
[TBL] [Abstract][Full Text] [Related]
3. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles.
Contreras-Ruiz L; de la Fuente M; García-Vázquez C; Sáez V; Seijo B; Alonso MJ; Calonge M; Diebold Y
Cornea; 2010 May; 29(5):550-8. PubMed ID: 20335805
[TBL] [Abstract][Full Text] [Related]
4. [Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma].
Schmidt KG; von Rückmann A; Becker R; Pillunat LE
Klin Monbl Augenheilkd; 1999 Dec; 215(6):361-6. PubMed ID: 10637801
[TBL] [Abstract][Full Text] [Related]
5. Allergic contact dermatitis from timolol and dorzolamide eye drops.
Kalavala M; Statham BN
Contact Dermatitis; 2006 Jun; 54(6):345. PubMed ID: 16787459
[No Abstract] [Full Text] [Related]
6. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group.
Adamsons I; Clineschmidt C; Polis A; Taylor J; Shedden A; Laibovitz R
J Glaucoma; 1998 Aug; 7(4):253-60. PubMed ID: 9713783
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.
Oyarzun-Ampuero FA; Brea J; Loza MI; Torres D; Alonso MJ
Int J Pharm; 2009 Nov; 381(2):122-9. PubMed ID: 19467809
[TBL] [Abstract][Full Text] [Related]
10. Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis.
Lu HD; Zhao HQ; Wang K; Lv LL
Int J Pharm; 2011 Nov; 420(2):358-65. PubMed ID: 21911044
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
12. Topical drug delivery to the eye: dorzolamide.
Loftsson T; Jansook P; Stefánsson E
Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010
[TBL] [Abstract][Full Text] [Related]
13. [Glaucoma: an ocular blood flow disorder?].
Recker K
Ophthalmologe; 2003 Feb; 100(2):2 p following 174. PubMed ID: 12650170
[No Abstract] [Full Text] [Related]
14. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits.
Warsi MH; Anwar M; Garg V; Jain GK; Talegaonkar S; Ahmad FJ; Khar RK
Colloids Surf B Biointerfaces; 2014 Oct; 122():423-431. PubMed ID: 25159319
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Lin A; Liu Y; Huang Y; Sun J; Wu Z; Zhang X; Ping Q
Int J Pharm; 2008 Jul; 359(1-2):247-53. PubMed ID: 18457928
[TBL] [Abstract][Full Text] [Related]
16. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation.
Fulgêncio Gde O; Viana FA; Ribeiro RR; Yoshida MI; Faraco AG; Cunha-Júnior Ada S
J Ocul Pharmacol Ther; 2012 Aug; 28(4):350-8. PubMed ID: 22320419
[TBL] [Abstract][Full Text] [Related]
17. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
18. [Trusopt--a new form of drug for treating glaucoma].
Izdebska J
Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571
[TBL] [Abstract][Full Text] [Related]
19. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin.
Chen MC; Wong HS; Lin KJ; Chen HL; Wey SP; Sonaje K; Lin YH; Chu CY; Sung HW
Biomaterials; 2009 Dec; 30(34):6629-37. PubMed ID: 19767097
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of nano-fiber patch for the treatment of glaucoma.
Gagandeep ; Garg T; Malik B; Rath G; Goyal AK
Eur J Pharm Sci; 2014 Mar; 53():10-6. PubMed ID: 24333373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
